John M. Maris

A generalizable system for antigenic peptide targeting across HLA-I allotypes

The paper develops a system to create binders compatible across HLA allotypes, validated against clinically relevant antigens and demonstrated in CAR T cells.

Specific HLA Class I and II alleles are associated with a higher risk for tumor formation in Neurofibromatosis type 1

The paper identifies specific HLA class I and II alleles associated with increased risk of certain tumor types in NF1 patients using RNA-seq and DNA sequencing data.

Atomically accurate de novo design of antibodies with RFdiffusion

This paper designs antibodies de novo with atomic precision using RFdiffusion and yeast display, validated by cryo-EM and biophysical methods.

A genome-wide association study in Chinese children identifies and functionally validates 5q31.1 as a neuroblastoma susceptibility locus

This paper identifies and validates 5q31.1 as a neuroblastoma susceptibility locus in Chinese children through GWAS and functional studies.

Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma

This paper identifies DLK1 as a novel immunotherapeutic target in adrenocortical carcinoma, showing it regulates tumor cell plasticity and chemoresistance, and demonstrates the efficacy of a DLK1-targeting antibody-drug conjugate.

IMMUNOTAR - Integrative prioritization of cell surface targets for cancer immunotherapy

IMMUNOTAR prioritizes and identifies immunotherapeutic targets by integrating RNA-sequencing and proteomics data with public databases to evaluate surface proteins across diverse criteria.

Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets

This paper identifies cell state-dependent and -independent immunotherapeutic targets in neuroblastoma by analyzing subtype-specific gene expression and validating targets through experimental methods.

The Open Pediatric Cancer Project

The paper introduces OpenPedCan, a harmonized multi-omic dataset of pediatric cancer patients, providing integrated genomic, transcriptomic, and proteomic data for research and clinical applications.

BPTF cooperates with MYCN and MYC to link neuroblastoma cell cycle control to epigenetic cellular states

This study shows BPTF works with MYCN and MYC to control cell cycle and epigenetic states in neuroblastoma, linking it to poor prognosis and therapeutic potential.

BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma

This study identifies BARD1 germline variants associated with reduced BARD1 expression and DNA repair defects in neuroblastoma, showing haploinsufficiency and increased genomic instability.

Germline pathogenic variants in 786 neuroblastoma patients

This study identifies 13.9% of neuroblastoma patients with pathogenic germline variants in cancer predisposition genes, associated with worse survival and enriched in DNA repair genes like BARD1.

annoFuse: an R Package to annotate, prioritize, and interactively explore putative oncogenic RNA fusions

annoFuse filters and prioritizes oncogenic gene fusions from RNA-Seq data, improving identification of clinically relevant fusions in cancer datasets.

Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma

This study identifies somatic structural variations in neuroblastoma, showing their enrichment in neurodevelopmental genes and the tumor suppressor role of SHANK2.

Epigenomic profiling of neuroblastoma cell lines

The paper provides ChIP-Seq and ATAC-Seq data for MYCN, MYC, and histone marks in neuroblastoma cell lines to study gene regulation and enhancer dynamics.

Genomic profiling of childhood tumor patient-derived xenograft models to enable rational clinical trial design

This paper genomically characterizes 261 pediatric cancer patient-derived xenograft models to guide rational clinical trial design and drug development.